Get the Stockscreener App
131.57
1.37%
-1.5791
Neurocrine Biosciences Inc stock is traded at $131.57, with a volume of 181.91K.
It is down -1.37% in the last 24 hours and up +1.08% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$133.15
Open:
$132.755
24h Volume:
181.91K
Relative Volume:
0.16
Market Cap:
$13.21B
Revenue:
$2.86B
Net Income/Loss:
$478.60M
P/E Ratio:
28.19
EPS:
4.6676
Net Cash Flow:
$748.70M
1W Performance:
-0.20%
1M Performance:
+1.08%
6M Performance:
-5.15%
1Y Performance:
+37.84%
1-Day Range:
$130.15
$133.17
1-Week Range:
$125.31
$134.20
52-Week Range:
$87.70
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
131.62 | 13.36B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
18.52 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
119.27 | 50.55B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.9901 | 44.44B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.77 | 35.54B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
580.84 | 25.49B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock - ChartMill
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - TradingView
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - Sahm
Momentum Shift: What hedge funds are buying Neurocrine Biosciences IncMarket Activity Recap & Verified Technical Trade Signals - baoquankhu1.vn
Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple - Yahoo Finance
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - The Economic Times
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $176 - Moomoo
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $242 - Moomoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology - The Chronicle-Journal
Neurocrine Biosciences (NASDAQ:NBIX) Given New $166.00 Price Target at Wedbush - MarketBeat
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²
RBC Capital Adjusts Neurocrine Biosciences PT to $176 From $177, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - IndexBox
Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to acquire Soleno in $2.9bn transaction - Pharmaceutical Technology
Neurocrine expands portfolio with buy of Soleno Therapeutics - The Pharma Letter
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition By Investing.com - Investing.com India
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition - Investing.com
Neurocrine to acquire Soleno in multi-billion dollar deal - marketscreener.com
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - Bitget
Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal - Yahoo Finance
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²
Neurocrine to seek Soleno (NASDAQ: SLNO) shares via tender offer - Stock Titan
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - axios.com
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - MedCity News
Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights
This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals
Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan
Wedbush raises Neurocrine Bio stock price target on acquisition By Investing.com - Investing.com India
Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - WHTC
Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView
Oppenheimer raises Neurocrine Biosciences price target on acquisition By Investing.com - Investing.com Canada
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily
Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com
Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today
American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU
Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):